Concord Drugs

{
  "main_header": {
    "sid": 605306,
    "name": "Concord Drugs",
    "stock_name": "Concord Drugs",
    "full_name": "Concord Drugs Ltd",
    "name_url": "stocks-analysis/concord-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "79.89",
    "chg": -0.82,
    "chgp": "-1.02%",
    "dir": -1,
    "prev_price": "80.71",
    "mcapval": "81.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 538965,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE858L01010",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "3.66 k",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/concord-drugs-605306-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "When is the next results date for Concord Drugs Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-concord-drugs-ltd-3819128",
        "imagepath": "",
        "date": "2026-02-03 23:16:55",
        "description": "The next results date for Concord Drugs Ltd is scheduled for 14 February 2026...."
      },
      {
        "title": "Concord Drugs Ltd Valuation Shifts to Fair Amidst Elevated Price Multiples",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-ltd-valuation-shifts-to-fair-amidst-elevated-price-multiples-3817088",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ConcordDrugsLtd_valuationdot_3817088.png",
        "date": "2026-02-03 08:00:47",
        "description": "Concord Drugs Ltd, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a significant shift in its valuation parameters, moving from an attractive to a fair rating. This change, coupled with a recent downgrade in its Mojo Grade from Hold to Sell, signals a critical juncture for investors assessing the stock’s price attractiveness amid evolving market dynamics."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3811006",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ConcordDrugsLtd_mojoScore_3811006.png",
        "date": "2026-01-30 10:11:27",
        "description": "Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3793976",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ConcordDrugsLtd_mojoScore_3793976.png",
        "date": "2026-01-19 10:10:32",
        "description": "Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3783041",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ConcordDrugsLtd_mojoScore_3783041.png",
        "date": "2026-01-06 10:10:43",
        "description": "Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3769487",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ConcordDrugsLtd_mojoScore_3769487.png",
        "date": "2025-12-25 15:13:16",
        "description": "Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Dec 2025. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Concord Drugs Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-upgraded-to-hold-by-marketsmojo-on-improving-technicals-and-valuation-3755930",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ConcordDrugs_mojoScore_3755930.png",
        "date": "2025-12-11 08:06:53",
        "description": "Concord Drugs, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its market evaluation, reflecting a complex interplay of technical momentum, valuation metrics, financial trends, and broader market performance. This article analyses the factors influencing the recent changes in the company's assessment and what they imply for investors."
      },
      {
        "title": "Concord Drugs Sees Revision in Market Evaluation Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-downgraded-to-sell-by-marketsmojo-amid-weak-fundamentals-3749817",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ConcordDrugs_mojoScore_3749817.png",
        "date": "2025-12-06 10:10:23",
        "description": "Concord Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a shift in analytical perspective. This adjustment follows a detailed review of the company’s recent financial and technical parameters, highlighting a complex picture of operational challenges and market momentum."
      },
      {
        "title": "Is Concord Drugs overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-concord-drugs-overvalued-or-undervalued-3742700",
        "imagepath": "",
        "date": "2025-12-03 08:14:03",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Understanding Concord Drugs’ Valuation Metrics</strong></p>\n<p>At first glance, Concord Drugs’ price-to-earnings (PE) ratio stands out at an elevated 135.16, which is significantly higher than many of its pharmaceutical peers. This figure typically implies a premium valuation, often justified by expectations of robust future earnings growth. However, the company’s price-to-book value of 2.28 and enterprise value to EBITDA (EV/EBITDA) ratio of 20.90 present a more nuanced picture. These multiples, while above average, are not excessively stretched when compared to the broader pharmaceutical sector.</p>\n<p>Moreover, the PEG ratio of 0.63 is particularly noteworthy. A PEG ratio below 1 generally indicates that the stock is undervalued relative to its earnings growth rate, suggesting that Concor..."
      }
    ],
    "total": 264,
    "sid": "605306",
    "stock_news_url": "https://www.marketsmojo.com/news/concord-drugs-605306"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Quarterly Results",
      "datetime": "02-Feb-2026",
      "details": "Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve Un-Audited financials Results for Quarter ending Dec 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "20-Jan-2026",
      "details": "Certificate under Reg 74(5) of SEBI (DP) regulations",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order",
      "datetime": "30-Dec-2025",
      "details": "Company has received purchase orders from various entities for supply of its products.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "14 Feb 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

When is the next results date for Concord Drugs Ltd?

2026-02-03 23:16:55

The next results date for Concord Drugs Ltd is scheduled for 14 February 2026....

Read full news article

Concord Drugs Ltd Valuation Shifts to Fair Amidst Elevated Price Multiples

2026-02-03 08:00:47

Concord Drugs Ltd, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a significant shift in its valuation parameters, moving from an attractive to a fair rating. This change, coupled with a recent downgrade in its Mojo Grade from Hold to Sell, signals a critical juncture for investors assessing the stock’s price attractiveness amid evolving market dynamics.

Read full news article

Concord Drugs Ltd is Rated Sell

2026-01-30 10:11:27

Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Concord Drugs Ltd is Rated Sell

2026-01-19 10:10:32

Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Concord Drugs Ltd is Rated Sell

2026-01-06 10:10:43

Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Concord Drugs Ltd is Rated Sell

2025-12-25 15:13:16

Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Dec 2025. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Concord Drugs Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-11 08:06:53

Concord Drugs, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its market evaluation, reflecting a complex interplay of technical momentum, valuation metrics, financial trends, and broader market performance. This article analyses the factors influencing the recent changes in the company's assessment and what they imply for investors.

Read full news article

Concord Drugs Sees Revision in Market Evaluation Amidst Mixed Financial Signals

2025-12-06 10:10:23

Concord Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a shift in analytical perspective. This adjustment follows a detailed review of the company’s recent financial and technical parameters, highlighting a complex picture of operational challenges and market momentum.

Read full news article

Is Concord Drugs overvalued or undervalued?

2025-12-03 08:14:03

Understanding Concord Drugs’ Valuation Metrics

At first glance, Concord Drugs’ price-to-earnings (PE) ratio stands out at an elevated 135.16, which is significantly higher than many of its pharmaceutical peers. This figure typically implies a premium valuation, often justified by expectations of robust future earnings growth. However, the company’s price-to-book value of 2.28 and enterprise value to EBITDA (EV/EBITDA) ratio of 20.90 present a more nuanced picture. These multiples, while above average, are not excessively stretched when compared to the broader pharmaceutical sector.

Moreover, the PEG ratio of 0.63 is particularly noteworthy. A PEG ratio below 1 generally indicates that the stock is undervalued relative to its earnings growth rate, suggesting that Concor...

Read full news article

View All News